Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz starts with Zessly in Germany

Executive Summary

Germany has become the launch market for Sandoz’Zessly (infliximab) biosimilar after the company’s Hexal affiliate introduced the rival to Merck Sharp & Dohme’s (MSD’s) Remicade on 15 November. Launch list prices for Zessly 100mg powder for concentrate range from €705.29 (US$804.00) for one 100mg vial to €3,467.28 for a pack of five, representing a modest 5% discount to MSD’s list price for Remicade.


Related Content

Sandoz Sets Forth On Quest To Raise Its Margins


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts